Self-assembled nanostructures of elastin- and resilin-based block copolypeptides with stimuli responsiveness and resilience for drug delivery system, tissue engineering and regenerative medicine and methods of preparing the same
11827679 · 2023-11-28
Assignee
Inventors
- Dong Woo Lim (Ansan-si, KR)
- Aamna Basheer (Ansan-si, KR)
- Jae Sang Lee (Ansan-si, KR)
- Min Jung Kang (Bucheon-si, KR)
Cpc classification
C08J2389/00
CHEMISTRY; METALLURGY
C07K14/78
CHEMISTRY; METALLURGY
A61K47/42
HUMAN NECESSITIES
A61L27/227
HUMAN NECESSITIES
A61K38/39
HUMAN NECESSITIES
International classification
A61K38/39
HUMAN NECESSITIES
A61K47/42
HUMAN NECESSITIES
A61L27/22
HUMAN NECESSITIES
C07K14/78
CHEMISTRY; METALLURGY
Abstract
The present disclosure relates to a self-assembled nanostructure of an elastin- and resilin-based block copolypeptide with stimuli responsiveness and resilience for drug delivery, tissue engineering and regenerative medicine, a method for preparing the same and application thereof. The diblock polypeptide reversibly forms a self-assembled micelle structure in response to temperature stimuli and a hydrogel prepared using the triblock polypeptide undergoes reversible sol-gel or gel-sol transition in response to temperature stimuli and exhibits enhanced mechanical strength due to chemical crosslinkages between tyrosine residues. With such superior properties, the diblock/triblock polypeptide of the present disclosure can be used for drug delivery systems, scaffolds for tissue engineering and kits for tissue or organ regeneration.
Claims
1. A resilin-based polypeptide (RBP) exhibiting a phase transition behavior, which consists of the amino acid sequence of SEQ ID NO: 44.
2. The resilin-based polypeptide (RBP) according to claim 1, which is encoded by the polynucleotide sequence of SEQ ID NO: 42.
3. A diblock polypeptide with a temperature responsiveness, represented by Formula 1, which consists of: a resilin-based polypeptide block; and an elastin-based polypeptide block exhibiting a phase transition behavior, which is connected to one end of the resilin-based polypeptide block: [Formula 1] [hydrophobic EBP].sub.m-[RBP].sub.n wherein n or m is independently an integer 1 or greater, the [RBP] is a resilin-based polypeptide block consisting of the amino acid sequence of SEQ ID NO: 44, and the [hydrophobic EBP] is an elastin-based polypeptide block selected from the group consisting of: VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG of SEQ ID NO: 1, VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG of SEQ ID NO: 2, and IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG of SEQ ID NO: 3; and wherein: i) when the [hydrophobic EBP] is the elastin-based polypeptide block of SEQ ID NO: 1, each X of the repeating pentapeptide consists of: A (Ala), G (Gly) and I (Ile) at a ratio of 1:4:1; K (Lys), G (Gly) and I (Ile) at a ratio of 1:4:1; D (Asp), G (Gly) and I (Ile) at a ratio of 1:4:1; E (Glu), G (Gly) and I (Ile) at a ratio of 1:4:1; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2; ii) when the [hydrophobic EBP] is the elastin-based polypeptide block of SEQ ID NO: 2, each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2; K (Lys), A (Ala) and F (Phe) at a ratio of 1:3:2; D (Asp), A (Ala) and F (Phe) at a ratio of 1:3:2; K (Lys) and F (Phe) at a ratio of 3:3; D (Asp) and F (Phe) at a ratio of 3:3; H (His), A (Ala) and I (Ile) at a ratio of 3:2:1; H (His) and G (Gly) at a ratio of 5:1; or G (Gly), C(Cys) and F (Phe) at a ratio of 1:3:2; and iii) when the [hydrophobic EBP] is the elastin-based polypeptide block of SEQ ID NO: 3, each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:4:1; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2.
4. The diblock polypeptide with a temperature responsiveness according to claim 3, wherein when the [hydrophobic EBP] is a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block of SEQ ID NO: 1, the [hydrophobic EBP] is SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, or SEQ ID NO: 31.
5. The diblock polypeptide with a temperature responsiveness according to claim 3, wherein when the [hydrophobic EBP] is a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block of SEQ ID NO: 2, the [hydrophobic EBP] is SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
6. The diblock polypeptide with a temperature responsiveness according to claim 3, wherein when the [hydrophobic EBP] is an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block of SEQ ID NO: 3, the [hydrophobic EBP] is SEQ ID NO: 40 or SEQ ID NO: 41.
7. The diblock polypeptide with a temperature responsiveness according to claim 3, wherein the diblock polypeptide undergoes a dynamic change in response to temperature, and wherein a [RBP] block core-[hydrophobic EBP] block shell micelle structure is formed through self-assembly at or below the lower critical solution temperature of the [hydrophobic EBP], an aggregate is formed at or above the lower critical solution temperature of the [hydrophobic EBP], and a [hydrophobic EBP] block core-[RBP] block shell micelle structure is formed at or above the upper critical solution temperature of the [RBP].
8. The diblock polypeptide with a temperature responsiveness according to claim 7, wherein the dynamic change is reversible in response to temperature.
9. A drug delivery composition comprising the diblock polypeptide according to claim 3.
10. A triblock polypeptide with a temperature responsiveness, represented by Formula 2, which consists of: a resilin-based polypeptide block; and elastin-based polypeptide blocks exhibiting a phase transition behavior, which are connected to both ends of the resilin-based polypeptide block: [Formula 2] [hydrophobic EBP].sub.m-[RBP].sub.n-[hydrophobic EBP].sub.m wherein n or m is independently an integer 1 or greater, the [RBP] is a resilin-based polypeptide block consisting of the amino acid sequence of SEQ ID NO: 44, and the [hydrophobic EBP] is an elastin-based polypeptide block selected from the group consisting of: VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG of SEQ ID NO: 1, VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG of SEQ ID NO: 2, and IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG of SEQ ID NO: 3; and wherein: i) when the [hydrophobic EBP] is the elastin-based polypeptide block of SEQ ID NO: 1, each X of the repeating pentapeptide consists of: A (Ala), G (Gly) and I (Ile) at a ratio of 1:4:1; K (Lys), G (Gly) and I (Ile) at a ratio of 1:4:1; D (Asp), G (Gly) and I (Ile) at a ratio of 1:4:1; E (Glu), G (Gly) and I (Ile) at a ratio of 1:4:1; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2; ii) when the [hydrophobic EBP] is the elastin-based polypeptide block of SEQ ID NO: 2, each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2; K (Lys), A (Ala) and F (Phe) at a ratio of 1:3:2; D (Asp), A (Ala) and F (Phe) at a ratio of 1:3:2; K (Lys) and F (Phe) at a ratio of 3:3; D (Asp) and F (Phe) at a ratio of 3:3; H (His), A (Ala) and I (Ile) at a ratio of 3:2:1; H (His) and G (Gly) at a ratio of 5:1; or G (Gly), C(Cys) and F (Phe) at a ratio of 1:3:2; and iii) when the [hydrophobic EBP] is the elastin-based polypeptide block of SEQ ID NO: 3, each X of the repeating pentapeptide consists of: G (Gly), A (Ala) and F (Phe) at a ratio of 1:4:1; or G (Gly), A (Ala) and F (Phe) at a ratio of 1:3:2.
11. The triblock polypeptide with a temperature responsiveness according to claim 10, wherein when the [hydrophobic EBP] is a [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG] block of SEQ ID NO: 1, the [hydrophobic EBP] is SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, or SEQ ID NO: 31.
12. The triblock polypeptide with a temperature responsiveness according to claim 10, wherein when the [hydrophobic EBP] is a [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG] block of SEQ ID NO: 2, the [hydrophobic EBP] is SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39.
13. The triblock polypeptide with a temperature responsiveness according to claim 10, wherein when the [hydrophobic EBP] is an [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] block of SEQ ID NO: 3, the [hydrophobic EBP] is SEQ ID NO: 40 or SEQ ID NO: 41.
14. A hydrogel prepared by a process comprising: applying a temperature, which is at or above the lower critical solution temperature of the [hydrophobic EBP], to the triblock polypeptide according claim 10, wherein the triblock polypeptide undergoes self-assembly and phase transition to form a physically crosslinked network.
15. The hydrogel according to claim 14, wherein the hydrogel undergoes reversible sol-gel or gel-sol transition in response to temperature.
16. The hydrogel according to claim 14, wherein the hydrogel has enhanced mechanical strength due to chemical crosslinkages between the tyrosine residues of the resilin-based polypeptide block.
17. A composition for drug delivery comprising the hydrogel according to claim 14.
18. A scaffold for tissue engineering comprising the hydrogel according to claim 14.
19. A kit for tissue or organ regeneration comprising the hydrogel according to claim 14.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
DETAILED DESCRIPTION OF THE INVENTION
(13) Hereinafter, specific examples are presented to help understanding the present disclosure. However, the following examples are given only to help better understanding of the present disclosure and the present disclosure is not limited by the examples.
EXAMPLES
Example 1. Materials
(14) The pET-21a vector and BL21 (DE3) E. coli cells were obtained from Novagen Inc. (Madison, Wisconsin, US). Top10 competent cells were obtained from Invitrogen (Carlsbad, California, US). Oligonucleotides were synthesized chemically at Cosmo Gene Tech (Seoul, South Korea). The FastAP thermosensitive alkaline phosphatase and restriction endonuclease including BamHI and XbaI were purchased from Fermentas (Ontario, Canada). Other restriction endonuclease including BseRI and AcuI and all other restriction enzymes were obtained from New England Biolabs (Ipswich, Massachusetts, US). DNA miniprep, gel extraction and PCR purification kits were obtained from Geneall Biotechnology (Seoul, South Korea). Dyne Agarose High was obtained from Dyne Bio, Inc. (Seongnam, South Korea). All the Top10 cells were grown in TB DRY media obtained from MO Bio Laboratories, Inc. (Carlsbad. California, US). All the BL21 (DE3) cells were grown in CircleGrow media obtained from MP Biomedicals (Solon, Ohio, US). Ready Gel (Tris-HCl 2-20%) as a precast gel was purchased from Bio-Rad (Hercules, California, US). Phosphate-buffered saline (PBS, pH 7.4), ampicillin and polyethyleneimine (PEI) were obtained from Sigma-Aldrich (St Louis, Missouri).
Example 2. Notation for Different EBP Blocks and their Block Polypeptides
(15) Different EBPs with a pentapeptide repeating unit, Val-Pro-(Gly or Ala)-X.sub.aa-Gly [VP(G or A)XG], where X.sub.aa can be any amino acid except Pro (SEQ ID NO:46 or SEQ ID NO:47), are named as follows. First, the pentapeptide repeat of Val-Pro-Ala-X.sub.aa-Gly (VPAXG) (SEQ ID NO:47) with plasticity is defined as an elastin-based polypeptide with plasticity (EBPP) while the pentapeptide repeat of Val-Pro-Gly-X.sub.aa-Gly (VPGXG) (SEQ ID NO:46) being called an elastin-based polypeptide with elasticity (EBPE). And, the pentapeptide repeat of Ile-Pro-Ala-X.sub.aa-Gly (IPAXG) (SEQ ID NO:49) wherein the first amino acid is substituted with Ile is defined as an elastin-based polypeptide with plasticity and substituted with Ile (EBPPI). Secondly, [X.sub.iY.sub.jZ.sub.k].sub.n represents that the bracketed capital letters are single letter amino acid codes of the guest residues, i.e. the amino acid at the fourth position (X.sub.aa or X) in the EBP pentapeptide, and their corresponding subscripts denote the ratio of that guest residue in the EBP monomer gene as the repeating unit. The subscript number n of [X.sub.iY.sub.jZ.sub.k].sub.n indicates the total repeating number of SEQ ID NO:1 [VPGXG VPGXG VPGXG VPGXG VPGXG VPGXG],-SEQ ID NO:2 [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG], or SEQ ID NO:3 [IPAXG IPAXG IPAXG IPAXG IPAXG IPAXG] in the EBP. For example, EBPP[G.sub.1A.sub.3F.sub.2].sub.12 is an EBPP block that contains 12 repeats of SEQ ID NO:2 [VPAXG VPAXG VPAXG VPAXG VPAXG VPAXG], in which the ratio of Gly, Ala and Phe at the fourth guest residue position (X.sub.aa) is 1:3:2.
(16) Two RBPs having different sequences are named as RBP[Dros].sub.n and RBP[m-Dros].sub.n, where n represents the number of repeating unit. Both sequences are derived from Drosophila exon 1 and the RBP repeating unit contains two repeating sequences of resilin. For RBP[Dros].sub.n, the repeating sequences are the same as reported in previous studies while, for RBP[m-Dros].sub.n, the two repeating sequences of resilin are combined with slight modifications to get the desired properties such as temperature responsiveness and high resilience. The EBPP-RBP diblock and triblock polypeptides are named by the composition of each block in square brackets with a hyphen between blocks such as EBPP[G.sub.1A.sub.3F.sub.2].sub.n-RBP[Dros/m-Dros].sub.n for a diblock and EBPP[G.sub.1A.sub.3F.sub.2].sub.n-RBP[Dros/m-Dros].sub.n-EBPP[G.sub.1A.sub.3F.sub.2].sub.n for a triblock.
Example 3. Preparation of Modified pET-21a Vector for Seamless Gene Cloning
(17) As shown in
Example 4. Monomer Gene Synthesis and Oligomerization for RBP and EBP
(18) The EBP sequences with a pentapeptide repeating unit, Val-Pro-(Gly or Ala)-X.sub.aa-Gly (SEQ ID NO:46 or SEQ ID NO:47), where the fourth residues are varied at different molar ratios were designed at DNA level to optimize T.sub.t below the physiological temperature. The DNA and amino acid sequences of the EBPs with various pentapeptide repeating units are shown in Table 1 and Table 2, respectively.
(19) TABLE-US-00004 TABLE 1 Gene sequences of EBP libraries EBP Gene Sequence EBPE[A.sub.1G.sub.4I.sub.1] GTC CCA GGT GGA GGT GTA CCC GGC GCG GGT GTC CCA GGT GGA GGT (SEQ ID NO: 4) GTA CCT GGG GGT GGG GTC CCT GGT ATT GGC GTA CCT GGA GGC GGC EBPP[A.sub.1G.sub.4I.sub.1] GTT CCA GCT GGC GGT GTA CCT GCT GCT GCT GTT CCG GCC GGT GGT (SEQ ID NO: 5) GTT CCG GCG GGC GGC GTG CCT GCA ATA GGA GTT CCC GCT GGT GGC EBPE[K.sub.1G.sub.4I.sub.1] GTT CCG GGT GGT GGT GTT CCG GGT AAA GGT GTT CCG GGT GGT GGT (SEQ ID NO: 6) GTT CCG GGT GGT GGT GGT GTT CCG GGT ATC GGT GTT CCG GGT GGC EBPP[K.sub.1G.sub.4I.sub.1] GTT CCG GCG GGT GGT GTT CCG GCG AAA GGT GTT CCG GCG GGT GGT (SEQ ID NO: 7) GTT CCG GCG GGT GGT GTT CCG GCG ATC GGT GTT CCG GCG GGT GGC EBPE[D.sub.1G.sub.4I.sub.1] GTT CCG GGT GGT GGT GTT CCG GGT GAT GGT GTT CCG GGT GGT GGT (SEQ ID NO: 8) GTT CCG GGT GGT GGT GGT GTT CCG GGT ATC GGT GTT CCG GGT GGC EBPP[D.sub.1G.sub.4I.sub.1] GTT CCG GCG GGT GGT GTT CCG GCG GAT GGT GTT CCG GCG GGT GGT (SEQ ID NO: 9) GTT CCG GCG GGT GGT GTT CCG GCG ATC GGT GTT CCG GCG GGT GGC EBPE[E.sub.1G.sub.4I.sub.1] GTT CCG GGT GGT GGT GTT CCG GGT GAA GGT GTT CCG GGT GGT GGT (SEQ ID NO: 10) GTT CCG GGT GGT GGT GGT GTT CCG GGT ATC GGT GTT CCG GGT GGC EBPP[E.sub.1G.sub.4I.sub.1] GTT CCG GCG GGT GGT GTT CCG GCG GAA GGT GTT CCG GCG GGT GGT (SEQ ID NO: 11) GTT CCG GCG GGT GGT GTT CCG GCG ATC GGT GTT CCG GCG GGT GGC EBPE[G.sub.1A.sub.3F.sub.2] GTC CCG GGT GCG GGC GTG CCG GGA TTT GGA GTT CCG GGT GCG GGT (SEQ ID NO: 12) GTT CCA GGC GGT GGT GTT CCG GGC GCG GGC GTG CCG GGC TTT GGC EBPP[G.sub.1A.sub.3F.sub.2] GTG CCG GCG GCG GGC GTT CCA GCC TTT GGT GTG CCA GCG GCG GGA (SEQ ID NO: 13) GTT CCG GCC GGT GGC GTG CCG GCA GCG GGC GTG CCG GCT TTT GGC EBPP[K.sub.1A.sub.3F.sub.2] GTG CCG GCG GCG GGC GTT CCA GCC TTT GGT GTG CCA GCG GCG GGA (SEQ ID NO: 14) GTT CCG GCC AAA GGC GTG CCG GCA GCG GGC GTG CCG GCT TTT GGC EBPP[D.sub.1A.sub.3F.sub.2] GTG CCG GCG GCG GGC GTT CCA GCC TTT GGT GTG CCA GCG GCG GGA (SEQ ID NO: 15) GTT CCG GCC GAT GGC GTG CCG GCA GCG GGC GTG CCG GCT TTT GGC EBPP[K.sub.3F.sub.3] GTT CCA GCG TTT GGC GTG CCA GCG AAA GGT GTT CCG GCG TTT GGG (SEQ ID NO: 16) GTT CCC GCG AAA GGT GTG CCG GCC TTT GGT GTG CCG GCC AAA GGC EBPP[D.sub.3F.sub.3] GTT CCA GCG TTT GGC GTG CCA GCG GAT GGT GTT CCG GCG TTT GGG (SEQ ID NO: 17) GTT CCC GCG GAT GGT GTG CCG GCC TTT GGT GTG CCG GCC GAT GGC EBPP[H.sub.3A.sub.3I.sub.1] GTG CCG GCG CAT GGA GTT CCT GCC GCC GGT GTT CCT GCG CAT GGT (SEQ ID NO: 18) GTA CCG GCA ATT GGC GTT CCG GCA CAT GGT GTG CCG GCC GCC GGC EBPP[H.sub.5G.sub.1] GTT CCG GCC GGA GGT GTA CCG GCG CAT GGT GTT CCG GCA CAT GGT (SEQ ID NO: 19) GTG CCG GCT CAC GGT GTG CCT GCG CAT GGC GTT CCT GCG CAT GGC EBPP[G.sub.1C.sub.3F.sub.2] GTG CCG GCG TGC GGC GTT CCA GCC TTT GGT GTG CCA GCG TGC GGA (SEQ ID NO: 20) GTT CCG GCC GGT GGC GTG CCG GCA TGC GGC GTG CCG GCT TTT GGC EBPPI[G.sub.1A.sub.4F.sub.1] ATT CCT GCA GCC GGT ATC CCG GCC GGT GGC ATT CCG GCA GCC GGC (SEQ ID NO: 21) ATT CCG GCC GCC GGC ATC CCG GCA TTT GGC ATT CCT GCA GCA GGC EBPPI[G.sub.1A.sub.3F.sub.2] ATT CCG GCC GCA GGC ATT CCT GCA TTT GGT ATT CCG GCG GCA GGC (SEQ ID NO: 22) ATT CCT GCC GGT GGC ATC CCG GCA GCG GGC ATT CCG GCC TTT GGC
(20) TABLE-US-00005 TABLE 2 Amino acid sequences of EBP libraries EBP Amino Acid Sequence EBPE[A.sub.1G.sub.4I.sub.1] VPGGG VPGAG VPGGG VPGGG VPGIG VPGGG (SEQ ID NO: 23) EBPP[A.sub.1G.sub.4I.sub.1] VPAGG VPAAG VPAGG VPAGG VPAIG VPAGG (SEQ ID NO: 24) EBPE[K.sub.1G.sub.4I.sub.1] VPGGG VPGKG VPGGG VPGGG VPGIG VPGGG (SEQ ID NO: 25) EBPP[K.sub.1G.sub.4I.sub.1] VPAGG VPAKG VPAGG VPAGG VPAIG VPAGG (SEQ ID NO: 26) EBPE[D.sub.1G.sub.4I.sub.1] VPGGG VPGDG VPGGG VPGGG VPGIG VPGGG (SEQ ID NO: 27) EBPP[D.sub.1G.sub.4I.sub.1] VPAGG VPADG VPAGG VPAGG VPAIG VPAGG (SEQ ID NO: 28) EBPE[E.sub.1G.sub.4I.sub.1] VPGGG VPGEG VPGGG VPGGG VPGIG VPGGG (SEQ ID NO: 29) EBPP[E.sub.1G.sub.4I.sub.1] VPAGG VPAEG VPAGG VPAGG VPAIG VPAGG (SEQ ID NO: 30) EBPE[G.sub.1A.sub.3F.sub.2] VPGAG VPGFG VPGAG VPGGG VPGAG VPGFG (SEQ ID NO: 31) EBPP[G.sub.1A.sub.3F.sub.2] VPAAG VPAFG VPAAG VPAGG VPAAG VPAFG (SEQ ID NO: 32) EBPP[K.sub.1A.sub.3F.sub.2] VPAAG VPAFG VPAAG VPAGG VPAAG VPAFG (SEQ ID NO: 33) EBPP[D.sub.1A.sub.3F.sub.2] VPAAG VPAFG VPAAG VPAGG VPAAG VPAFG (SEQ ID NO: 34) EBPP[K.sub.3F.sub.3] VPAFG VPAKG VPAFG VPAKG VPAFG VPAKG (SEQ ID NO: 35) EBPP[D.sub.3F.sub.3] VPAFG VPADG VPAFG VPADG VPAFG VPADG (SEQ ID NO: 36) EBPP[H.sub.3A.sub.3I.sub.1] VPAHG VPAAG VPAHG VPAIG VPAHG VPAAG (SEQ ID NO: 37) EBPP[H.sub.5G.sub.1] VPAGG VPAHG VPAHG VPAHG VPAHG VPAHG (SEQ ID NO: 38) EBPP[G.sub.1C.sub.3F.sub.2] VPACG VPAFG VPACG VPAGG VPACG VPAFG (SEQ ID NO: 39) EBPPI[G.sub.1A.sub.4F.sub.1] IPAAG IPAGG IPAAG IPAAG IPAFG IPAAG (SEQ ID NO: 40) EBPPI[G.sub.1A.sub.3F.sub.2] IPAAG IPAFG IPAAG IPAGG IPAAG IPAFG (SEQ ID NO: 41)
(21) In Table 1, SEQ ID NOS 4-11 may be classified as gene sequences for hydrophilic EBP blocks and SEQ ID NOS 12-22 may be classified as gene sequences for Phe- and His-containing hydrophobic EBP blocks. In Table 2, SEQ ID NOS 23-30 may be classified as hydrophilic and SEQ ID NOS 31-41 containing Phe and His may be classified as hydrophobic EBP blocks. That is to say, hydrophobicity is exhibited when the LOST of EBP is below the body temperature and hydrophilicity is exhibited when the LOST of EBP is above the body temperature. Therefore, the hydrophilicity and hydrophobicity of the EBP may be defined relatively with regard to bioengineering applications.
(22) Different EBPs having the pentapeptide repeating unit Val-Pro-(Gly or Ala)-X.sub.aa-Gly [where X.sub.aa can be any amino acid except Pro] (SEQ ID NO:46 or SEQ ID NO:47) were designed at DNA level to have unique responsiveness to stimuli including temperature and pH. Both the EBP with plasticity (EBPP) having the Val-Pro-Ala-X.sub.aa-Gly (VPAXG) (SEQ ID NO:47) pentapeptide repeats and the EBP with elasticity (EBPE) having the Val-Pro-Gly-X.sub.aa-Gly (VPGXG) (SEQ ID NO:46) pentapeptide repeats were replicated to have the same guest residue composition and ratio. The gene and amino acid sequences of the EBPs with different pentapeptide repeating units are shown in Table 1 and Table 2, respectively. For example, EBPE[G.sub.1A.sub.3F.sub.2].sub.12 and EBPP[G.sub.1A.sub.3F.sub.2].sub.12 show not only almost the same molar mass and but also the same combination of the fourth residue of the EBP pentapeptide repeating unit. They have different mechanical properties due to the difference in the third amino acid residue (Ala or Gly) of the pentapeptide repeating unit. Positively and negatively charged EBPs were constructed by introducing charged amino acids such as Lys, Asp, Glu, His, etc. as guest residues. In addition, in order to investigate the effect of the first amino acid (“Val” or “Ile”) on temperature responsiveness and physical crosslinking of the triblock polypeptide, the first amino acid “Val” of the pentapeptide unit was substituted with “Ile”, i.e., Ile-Pro-Ala-X.sub.aa-Gly (IPAXG) (SEQ ID NO:49).
(23) 50 μL of each pair of oligonucleotides for encoding various EBPs at 2 μM concentration in T4 DNA ligase buffer were annealed by heating at 95° C. for 2 minutes and then slowly cooled down to the room temperature over 3 hours. The resulting dsDNA products have nonpalindromic, 2 bp, 3′ overhangs. A total of 4 μg of the modified pET-21a(+)vector was digested with 15 U of BseRI in FastDigest buffer for 30 minutes at 37° C. The 5′ ends were dephosphorylated with 10 U of CIP in NEB 3 buffer for 1 hour at 37° C. The restricted vector was purified using the PCR purification kit and was eluted in 40 μL of distilled deionized water. The dsDNA was inserted into the linearized and modified pET-21a(+) vector by incubating 90 pmol of the annealed dsDNA and 30 pmol of the vector in T4 DNA ligase buffer containing T4 DNA ligase at 16° C. for 30 minutes. The ligated vector was introduced into chemically transformed Top10 competent cells, and then plated on SOC (Super Optimal Broth with catabolite repression) plates supplemented with 50 μg/mL of ampicillin. The insert sequence was confirmed by DNA sequencing.
(24) Two RBPs, RBP[Dros].sub.n and RBP[m-Dros].sub.n, were derived from Drosophila exon 1. The RBP[Dros].sub.n sequence was reported in previous studies with a repeating sequence of GGRPSDTYGAPGGGN (SEQ ID NO:53). But, in the present disclosure, two sequences were combined in the repeating unit to have same molecular weight as RBP[m-Dros].sub.n. The RBP[m-Dros].sub.n was RBP[Dros].sub.n modified with two repeating sequences of GGRPSDSYGAPGGGN (SEQ ID NO:54) and GGRPSSSYGAPGQGN (SEQ ID NO:55). The nucleotide and amino acid sequences of RBP[Dros].sub.1 and RBP[m-Dros].sub.i are given in Table 3 and Table 4, respectively.
(25) TABLE-US-00006 TABLE 3 Gene sequences of RBP libraries RBP Gene Sequence RBP[m-Dros].sub.1 GGC GGC CGT CCG TCA GAT TCT TAT GGC GCA CCG GGT GGG GGT AAT (SEQ ID NO: 42) GGC GGC CGT CCA TCT TCG AGC TAT GGC GCA CCG GGC CAA GGT AAT RBP[Dros].sub.1 GGG GCG CCG GGT GGT GGC AAC GGT GGT CGT CCG AGC GAT ACC TAC (SEQ ID NO: 43) GGG GCG CCG GGT GGT GGC AAC GGT GGT CGT CCG AGC GAT ACC TAC
(26) TABLE-US-00007 TABLE 4 Amino acid sequences of RBP libraries RBP Amino Acid Sequence RBP[m-Dros]1 GGRPSDSYGAPGGGN GGRPSSSYGAPGQGN (SEQ ID NO: 44) RBP[Dros]1 GGRPSDTYGAPGGGN GGRPSDTYGAPGGGN (SEQ ID NO: 45)
(27) As shown in
Example 5. Expression/Purification and Characterization of RBP
(28) The RBP[Dros].sub.n and RBP[m-Dros].sub.n gene containing plasmids were transformed into E. coli BL21 (DE3) cells. A single bacterial colony was inoculated into 10 mL of TB media (1st primary culture) containing 50 mg/mL ampicillin and incubated at 37° C. for overnight growth at 150 rpm. 400 mL of TB medium supplemented with 50 mg/mL ampicillin was inoculated with the 1st primary culture in a 2-L flask and incubated at 37° C. for 4 hours at 200 rpm. The 2nd primary culture was inoculated into 500 mL of CircleGrow containing trace elements in a 2-L flask and incubated at 37° C. and 200 rpm. Bacterial cells were harvested by centrifugation and cell pellets were resuspended in PBS. Cells lysate was obtained by sonicating the resuspended sample on an ice bath for 5 minutes at 50% power (10 seconds on with 20-second intervals).
(29) RBP[Dros].sub.n was purified by the ammonium sulfate precipitation and heating method as described in previous literatures with slight modifications. The sonicated sample was centrifuged at 16000 rpm for 30 minutes at 4° C. to remove insoluble cell debris and a PEI solution (0.5%) was added to the supernatant. Nucleic acid contaminants were separated by centrifuging at 16000 rpm for 15 minutes at 4° C. The clear soluble lysate was used for the purification of RBP[Dros]. The ammonium sulfate salt at final saturation of 30% was slowly added to the PEI-treated sample at 4° C. with stirring, mixed completely and kept for 20 minutes. Aggregated proteins were separated by centrifugation at 16000 rpm for 20 minutes at 4° C. and the pellet was resuspended in PBS. RBP[Dros].sub.n was separated with 20% s ammonium sulfate by centrifuging under the same condition as described above. The supernatant was discarded and the pellet was resuspended in PBS. The sample was dialyzed in excess PBS to remove the ammonium sulfate salt. A high-purity product was obtained using the thermal stability of RBP[Dros].sub.n and the sample was heated at 90° C. for 5 minutes with stirring which denatured the contaminated proteins. The RBP[Dros].sub.n was maintained in solubilized state even under the high temperature condition. The denatured proteins were removed by centrifuging at 13000 rpm for 20 minutes at room temperature. The pellet was discarded and pure RBP[Dros].sub.n existing in the supernatant was stored for further use.
(30) For purification of the RBP[m-Dros].sub.n, the sonicated sample was centrifuged at 16000 rpm for 30 minutes at 4° C. The supernatant was discarded and the cell pellet was resuspended in 3-5 mL of PBS. The sample was heated at 65° C. for 20 minutes for complete solubilization and the heated sample was centrifuged at 16000 rpm for 15 minutes at room temperature to remove the contaminated proteins. The RBP[m-Dros].sub.n remained in the supernatant because of its solubility at high temperature. The supernatant was cooled at 4° C. for 30 minutes and then cooled to −20° C. for 5 minutes to trigger the phase transition of the RBP[m-Dros].sub.n which was visible due to increased turbidity. The aggregated proteins were separated by centrifugation at 16000 rpm for 10 minutes at 4° C. and the cell pellet was suspended in PBS at room temperature. The solubilization at high temperature and aggregation cycles at low temperature were continued for 3 more times to get purified proteins.
(31) Purity and molecular weight were analyzed by SDS-PAGE for Coomassie-stained RBP[Dros].sub.n and copper-stained RBP[m-Dros].sub.n. The phase transition behavior of the RBP[m-Dros].sub.n was characterized by UV-visible spectrophotometry and dynamic light scattering (DLS). For the lower critical solution temperature, the 25 μM sample solution was heated to 50° C. and then optical density at 350 nm (OD.sub.350) was measured from 50° C. to 10° C. as a function of temperature at a cooling rate of 1° C./min.
(32) Through the agarose gel electrophoresis analysis, RBP[Dros].sub.n and RBP[m-Dros].sub.n gene libraries having various repeating units from 336 bp to 2766 bp were identified (
(33) TABLE-US-00008 TABLE 5 Expected molecular weight of RBP[m-Dros].sub.n and RBP[Dros].sub.n multimerized by RDL RBP monoblock polypeptides MW (kDa) RBP[m-Dros].sub.3 8.48 RBP[m-Dros].sub.6 16.59 RBP[m-Dros].sub.12 32.81 RBP[m-Dros].sub.24 65.26 RBP[m-Dros].sub.30 81.48 RBP[Dros].sub.3 8.44 RBP[Dros].sub.6 16.50 RBP[Dros].sub.8 21.30 RBP[Dros].sub.12 32.63 RBP[Dros].sub.16 43.39 RBP[Dros].sub.24 64.90 RBP[Dros].sub.30 81.03
(34)
Example 6. Synthesis and Expression of EBPP-RBPP Diblock Polypeptide Gene
(35) As seen from
(36) For expression of fusion proteins, the pET-21a(+) vector containing EBPP-RBP polypeptides was transformed into E. coli BL21(DE3) cells. A single colony was inoculated into 50 mL of CircleGrow media in 250-mL flasks containing 50 μg/mL of ampicillin, and subsequently used to inoculate CircleGrow media in 2-L flasks. The flasks were incubated on a shaking incubator at 200 rpm and expression was induced by adding IPTG at a final concentration of 1 mM when the optical density (OD.sub.600) reached 1.0. The cultures were harvested after 18 hours of incubation and the fusion proteins were purified by ITC. The cell pellets were resuspended in PBS, and the cells lysate was obtained by sonicating the samples (VC-505, Sonic and Materials Inc., Danbury, Connecticut) on an ice bath. The cells debris was separated by centrifugation at 16000 rpm for 15 minutes at 4° C. and the soluble lysate was transferred to a fresh tube. Then a PEI solution was added to a final concentration of 0.5% w/v and mixed well. Nucleic acid contaminants were separated by centrifuging at 16000 rpm for 15 minutes at 4° C. Sodium chloride was added at a final concentration of 3-4 M to the PEI-treated samples to trigger the phase transition of the fusion proteins. The aggregated fusion proteins were separated by centrifuging at 16000 rpm for 30 minutes at 40° C. The aggregated fusion proteins were resuspended in cold PBS, and the samples were centrifuged at 16000 rpm for 15 minutes at 4° C. to remove any remaining insoluble matter. This aggregation and resuspension process was repeated 4-5 times until an appropriate purity of the fusion proteins was obtained.
Example 7. Physicochemical Properties of EBPP-RBP Diblock Polypeptide
(37)
(38) TABLE-US-00009 TABLE 6 Expected molecular weight and transition temperature of EBPP-RBP diblock peptide having different block lengths EBPP-RBP diblock polypeptides MW (kDa) T.sub.tS EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.3 23.55 44.5 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.6 31.66 48.9 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.12 47.88 47.9 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.24 80.32 55.4 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.3 38.61 36.62 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6 46.72 33.21 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.12 62.94 31.49 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.24 95.39 28.00 EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.3 23.50 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.6 31.57 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.12 47.70 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[Dros].sub.24 79.96 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.3 38.57 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.6 46.63 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.12 62.76 N/A EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[Dros].sub.24 95.03 N/A
(39) The molecular weight of the diblock polypeptide varied from 23.55 to 95.03 kDa.
(40) At this temperature, the EBPP[G.sub.1A.sub.3F.sub.2].sub.6 serves as a core and the RBP[m-Dros].sub.24 serves as a shell. Whereas the UCST of the monoblock is −18° C., the fusion of EBPP[G.sub.1A.sub.3F.sub.2].sub.6 and RBP[m-Dros].sub.24 resulted in increased UCST because the aggregated state is maintained until the thermal transition of the EBPP[G.sub.1A.sub.3F.sub.2].sub.6. For the EBPP[G.sub.1A.sub.3F.sub.2].sub.6-RBP[m-Dros].sub.3, a micelle was not formed because the effect of the EBPP[G.sub.1A.sub.3F.sub.2].sub.6 was dominant throughout the temperature range due to the small molecular weight.
(41)
Example 8. Synthesis and Expression of EBPP-RBP-EBPP Triblock Polypeptide Gene
(42) EBPP-RBP-EBPP triblock peptides were synthesized in two steps. In the first step, a RBP-EBPP block copolymer was formed by inserting the RBP gene into an EBPP-containing plasmid. In the second step, the EBPP gene was inserted into the RBP-EBPP-containing plasmid. For vector preparation, 4 μg of the plasmid was digested with 15 U of BseRI and 10 U of XbaI in FastDigest buffer for 30 minutes at 37° C. The 5′ ends were dephosphorylated with 10 U of CIP in NEB 3 buffer for 1 hour at 37° C. The restricted vector was purified using the PCR purification kit. For insertion, the plasmid was doubly digested with 10 U of XbaI and 15 U of AcuI for 30 minutes at 37° C. The digested product was separated by agarose gel electrophoresis and purified using the PCR purification kit. Ligation was carried out by incubating 90 pmol of the purified insert and 30 pmol of the linearized vector in T4 DNA ligase buffer containing 1 U of T4 DNA ligase at 16° C. for 30 minutes. E. coli Top 10 competent cells were transformed with the ligated product and then spread on SOC plates supplemented with 50 μg/mL of ampicillin. Triblock polypeptides with different EBP lengths and RBP genes were synthesized and all block lengths were checked by agarose gel electrophoresis after restriction by XbaI and AcuI and further confirmed by DNA sequencing. Then, the expression of fusion proteins was conducted in the same manner as in Example 6.
Example 9. Physicochemical Properties of EBPP-RBP-EBPP Triblock Polypeptide
(43)
(44) Under physiological conditions and above the T.sub.t, the hydrophobic EBPP block self-assembled with the hydrophilic RBP middle block containing the tyrosine residues to form a physically crosslinked hydrogel. The mechanical properties of the physically crosslinked hydrogel was enhanced by the chemical crosslinkages of the tyrosine residues on the RBP block. The expected molecular weight and transition temperature (T.sub.t) depending on the lengths of the hydrophobic block and the RBP[m-Dros].sub.n when EBPP[G.sub.1A.sub.3F.sub.2].sub.12 or EBPP[G.sub.1A.sub.3F.sub.2].sub.24 is fused with RBP[m-Dros].sub.n of various lengths are given in Table 7. In addition, in order to confirm the effect of physical crosslinking, EBPP or EBPPI libraries differing only in the first amino acid residue of the pentapeptide repeating unit (“Val” or “Ile”) were fused with the same RBP[m-Dros] block.
(45) TABLE-US-00010 TABLE 7 Expected molecular weight and transition temperature of EBPP(I)- RBP-EBPP(I) triblock peptides having different block lengths EBPP-RBP-EBPP triblock polypeptides MW (kDa) T.sub.tS EBPPI[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPPI[G.sub.1A.sub.3F.sub.2].sub.12 78.9 14.5 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPP[G.sub.1A.sub.3F.sub.2].sub.12 76.8 29.74 EBPP[G.sub.1A.sub.3F.sub.2].sub.24-RBP[m-Dros].sub.6-EBPP[G.sub.1A.sub.3F.sub.2].sub.24 137.1 25.59 EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.12-EBPP[G.sub.1A.sub.3F.sub.2].sub.12 93.1 27.86 EBPP[G.sub.1A.sub.3F.sub.2].sub.24-RBP[m-Dros].sub.12-EBPP[G.sub.1A.sub.3F.sub.2].sub.24 153.3 23.10
(46) The transition temperature was decreased as the EBPP[G.sub.1A.sub.3F.sub.2] block length was increased. In particular, the triblock polypeptides having EBPPI libraries showed much lower transition temperatures (T.sub.t) than the triblock polypeptides of the same block lengths having EBPP libraries. That is to say, the LOST of EBPPI[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPPI[G.sub.1A.sub.3F.sub.2].sub.12 was much lower than that of the EBPP[G.sub.1A.sub.3F.sub.2].sub.12-RBP[m-Dros].sub.6-EBPP[G.sub.1A.sub.3F.sub.2].sub.12 triblock polypeptide of the same block length but having EBPP library. Such a significant decrease in T.sub.t is due to the substitution of “Val” in the first position of the pentapeptide repeat with the relatively more hydrophobic “Ile”.
(47)
(48)
(49)
Example 10. Rheological Measurement of EBPP-RBP-EBPP Triblock Polypeptide
(50) Various concentrations of EBPP-RBP-EBPP polypeptide solutions were prepared using phosphate-buffered saline (PBS, pH 7.4) and subjected to dynamic-shear rheological test to measure the elastic modulus (G′), loss modulus (G″), complex shear modulus (G*), complex viscosity (η*) and loss angle (δ) as functions of temperature and frequency. The G′ characterizes the elastic behavior of a material while the G″ characterizes its viscous behavior. G* and η* represent the frequency-dependent stiffness and the frequency-dependent viscous drag of a viscoelastic liquid or solid, respectively. The loss angle (δ) is a relative measure of viscous to elastic properties (Newtonian viscous fluid: δ=90°; elastic solid: δ=0°). A metal solvent trap under fully hydrating conditions was used to prevent solvent evaporation over temperatures ranging from 10° C. to 40° C. Dynamic frequency sweep measurements were performed in the linear viscoelastic regime at different temperatures, as confirmed by independent strain sweep tests (strain sweep range: 0.2-20%, angular frequency: 0.1, 1.0 or 10 rad/s). The angular frequency ranged from 1.0 to 100 rad/s, both at 10° C. (below T.sub.t) and 40° C. (above T.sub.t) for the frequency sweep tests. The temperature sweep tests were executed with 2% strain at 1 rad/s over a temperature range of 10° C. to 45° C. with one-minute duration per degree for forward heating and reverse cooling measurements to examine the reversibility of their rheological and mechanical properties. All measurements were made 3 times to ensure reproducibility.
(51)
(52)
(53) The present invention has been described in detail with reference to specific embodiments thereof. However, it will be appreciated by those skilled in the art that various changes and modifications may be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.